Inmagene Biopharmaceuticals Posts Positive Results for IMG-007 in Atopic Dermatitis
Inmagene Biopharmaceuticals, a Sino-US biotech that recently merged with US-based Ikena Oncology, Inc. (NASDAQ: IKNA),...
Inmagene Biopharmaceuticals
Ikena Oncology and Inmagene Biopharmaceuticals to Merge into ImageneBio, Listed on Nasdaq as ‘IMA’
US-based Ikena Oncology, Inc. (NASDAQ: IKNA) and Sino-US biotech Inmagene Biopharmaceuticals have announced their merger...
Inmagene Biopharmaceuticals and Aditum Bio Launch JV Celexor Bio to Target Autoimmune Diseases
Inmagene Biopharmaceuticals, a China-based biopharmaceutical company, has announced a strategic collaboration with US firm Aditum...
Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis
China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...
Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...
Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study
China-based Inmagene Biopharmaceuticals and Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the...